Tezspire is the only biologic medication to target thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of the inflammatory cascade and can drive multiple inflammatory pathways and airway hyperresponsiveness.

Tezspire is indicated for the add-on maintenance treatment of adults and pediatric patients 12 years old and older with severe asthma. This medication is not for acute treatment of asthma or status asthmaticus.

Asthma causes airway inflammation and airway hyperresponsiveness. The airway epithelium is the first contact with viruses, pollutants, and allergens which can cause the release of TSLP which may lead to inflammatory pathways.

This medication has been shown to decrease airway inflammation and airway hyperresponsiveness. Blocking TSLP has been shown to reduce 3 biomarkers over time, eosinophils, IgE and fractional exhaled nitric oxide as well as impacting tissue eosinophils and reduction in airway hyperresponsiveness.